1. Home
  2. ATXS vs AIO Comparison

ATXS vs AIO Comparison

Compare ATXS & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astria Therapeutics Inc.

ATXS

Astria Therapeutics Inc.

HOLD

Current Price

$12.96

Market Cap

722.1M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest

AIO

Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest

HOLD

Current Price

$22.43

Market Cap

805.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATXS
AIO
Founded
2008
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
722.1M
805.3M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ATXS
AIO
Price
$12.96
$22.43
Analyst Decision
Hold
Analyst Count
6
0
Target Price
$24.33
N/A
AVG Volume (30 Days)
1.3M
141.5K
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
9.05%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$706,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.56
$15.09
52 Week High
$13.29
$20.25

Technical Indicators

Market Signals
Indicator
ATXS
AIO
Relative Strength Index (RSI) 65.58 38.14
Support Level $12.70 $22.88
Resistance Level $13.29 $23.20
Average True Range (ATR) 0.22 0.46
MACD -0.05 -0.01
Stochastic Oscillator 67.34 33.22

Price Performance

Historical Comparison
ATXS
AIO

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest

Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.

Share on Social Networks: